Jay Olson
Research Analyst Oppenheimer & Company
Jay Olson is Managing Director and Senior Analyst covering Biotechnology. Prior to joining Oppenheimer, Jay covered SMID-cap names and worked on the Large Cap Pharmaceuticals team at Goldman Sachs for 4 years after 4 years on the #1 II-ranked Large Cap Pharmaceuticals team at Sanford Bernstein. Prior to Wall Street, Jay spent 18 years in the pharmaceutical industry, working mostly for Pfizer in finance, marketing and business development. Jay received an MBA in Finance and an MS in Chemical Engineering both from MIT, and a BS in Chemical Engineering from Tufts University. He also holds the CFA designation.
Seminars
Thursday 3rd December 2026
Navigating the Funding Landscape to Accelerate Indication-Agnostic Amylin R&D
2:30 pm
- Gain insight into where investor appetite is building across selective agonists, combination approaches, oral molecules, antibodies and long-acting amylin strategies
- Understand the key financing stages from seed and Series A through clinical development, strategic partnerships and late-stage capital
- Identify the scientific and clinical milestones investors need to see to de-risk amylin programmes and support the next funding round
- Learn how to articulate a differentiated value proposition around receptor strategy, efficacy, tolerability, modality, patient positioning and indication expansion to attract investment and strategic partners
